
# ADELA: a double-blind, placebo-controlled, randomized phase 3 trial of elacestrant + everolimus versus elacestrant + placebo in ER+/HER2advanced breast cancer patients with ESR1-mutated tumors progressing on endocrine therapy + CDK4/6 inhibitor

1 Seain; <sup>3</sup> Universidad Católica Valencia, Spain; <sup>4</sup> International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain; <sup>4</sup> International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Porto Alegre, Brazil Oncoclinicas Group, Brazil Oncoclinicas Group, Porto Alegre, Brazil Oncoclinicas Group, Brazil Oncocli Alegre, Brazil; <sup>6</sup>European Institute of Oncology, Vienna, Austria; <sup>8</sup>Hôpital Privé des Côtes d'Armor-Centre CARIO; <sup>9</sup>Menarini Group, New York, NY, USA; <sup>11</sup>Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain; <sup>12</sup>IOB Madrid, Institute of Oncology, Hospital Beata Maria Ana, Madrid, Spain.


# BACKGROUND

- Endocrine therapy plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i) is the standard-of-care (SOC) in first-line estrogen receptor-positive (ER+)/HER2-negative (HER2-) advanced breast cancer (aBC);<sup>1-3</sup> however, tumors eventually develop resistance.<sup>4</sup>
- Constitutive activation of the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway can contribute to endocrine resistance in breast cancer.<sup>5-11</sup>
- A common type of acquired resistance mechanism consists of alterations in the estrogen receptor 1 gene (ESR1). ESR1-mutated tumors occur in 40%-50% of patients with BC and predominantly emerge in the metastatic setting after prolonged exposure to aromatase inhibitor (AI) regimens.<sup>5,12-18</sup> • There is an unmet need for novel therapeutic approaches to overcome different resistance mechanisms and improve clinical outcomes in patients with
- ER+/HER2- aBC with ESR1-mutated tumors who progress following ET+CDK4/6i.
- Elacestrant is a next-generation oral selective ER degrader (SERD) that binds to the ER alpha and induces its degradation.<sup>19</sup>
- In the pivotal phase 3 EMERALD study, single-agent elacestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus SOC ET in patients with ESR1-mutated tumors (HR = 0.55; 95% CI, 0.39-0.77; P = 0.0005).<sup>20</sup> - Differences were particularly notable among patients who received prior ET+CDK4/6i ≥12 months; median PFS with elacestrant was 8.6 months vs 1.9 months with SOC ET (HR = 0.41; 95% CI, 0.26-0.63).<sup>21</sup>
- The crosstalk between the ER and PI3K/AKT/mTOR pathways are additional mechanisms of resistance to endocrine treatment and provides a rationale for evaluating the combination of elacestrant with specific PI3K/AKT/mTOR inhibitors.<sup>22,23</sup>
- Everolimus, an mTOR complex 1 (mTORC1) inhibitor, is indicated for the treatment of postmenopausal women with hormone receptor-positive (HR+)/HER2- aBC in combination with exemestane after progression on non-steroidal Als.<sup>24</sup>
- In preclinical models of ER+ breast cancer, the combination of elacestrant + everolimus showed significantly greater tumor growth inhibition.<sup>25</sup>
- The recommended phase 2 dose (elacestrant 345 mg QD + everolimus 7.5 mg QD) was consistent with the known safety profile for everolimus + SOC ET.<sup>26,27</sup> - Preliminary efficacy data demonstrated antitumor activity with the combination (elacestrant + everolimus): objective response rate = 22%; clinical benefit rate at
- 24 weeks = 72%.<sup>26</sup>

### Rationale for Evaluating the Combination of Elacestrant With Specific PI3K/AKT/mTOR Inhibitors in **ER+/HER2- aBC**<sup>22,23</sup>



### In Preclinical Models of ER+ Breast Cancer, the Combination of Elacestrant + Everolimus Showed Significantly **Greater Tumor Growth Inhibition**<sup>24</sup>



Antonio Llombart-Cussac,<sup>1,2,3</sup> José Manuel Pérez-García,<sup>1,4</sup> Elena Lopez-Miranda,<sup>1</sup> Rui Rui Zhang,<sup>1</sup> Miguel Sampayo-Cordero,<sup>1</sup> Juliana Carvalho-Santos,<sup>1</sup> Pablo Gili Pozo,<sup>1</sup> Marta Beltran,<sup>1</sup> Carlos H. Barrios,<sup>5</sup> Giuseppe Curigliano,<sup>6</sup> Rupert Bartsch,<sup>7</sup> Anne Clair Hardy Bessard,<sup>8</sup> Anna Compagnoni,<sup>9</sup> Kathy Puyana Theall,<sup>10</sup> Thomas Buechele,<sup>9</sup> Tomer Wasserman,<sup>9</sup> Javier Cortés<sup>1,4,11,12</sup>

# OBJECTIVE


ER+/HER2- advanced breast cancer and *ESR1*-mutated tumors progressing on ET + CDK4/6i.

## METHODS

- ADELA is an international, multicenter, double-blind, placebo-controlled, randomized phase 3 trial.
- Patients will be randomized in a 1:1 ratio to receive elacestrant + everolimus or elacestrant + placebo until disease progression or unacceptable toxicity. Elacestrant 345 mg once daily (QD) + everolimus 7.5 mg QD
- Elacestrant 345 mg QD + placebo QD
- Patients will receive the study treatment in 28-day cycles until the earliest occurrence of documented disease progression, death, unacceptable toxicity, or discontinuation from the study treatment for any other reason.
- Patients will receive dexamethasone mouthwashes four times daily during the first 8 weeks and at the investigator's discretion for an additional 8 weeks.
- A total of 240 patients will be randomized.

### ADELA Study Design

#### A phase 3 study of elacestrant ± everolimus in patients with ER+/HER2- aBC and ESR1-mut tumors who progressed on prior ET + CDK4/6i



\*Elacestrant 345 mg is equivalent to 400 mg elacestrant hydrochloride. †Recommended phase 2 dose (RP2D) for everolimus from ELEVATE (NCT05563220) trial. ‡Through the use of RECIST v.1.1. §Based on BIRC and local investigator assessment through use of RECIST v.1.7 aBC, advanced breast cancer; BIRC, blinded independent review committee; CBR, clinical benefit rate; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; DoR, duration of response; ER, estrogen receptor; ESR1, estrogen receptor 1 gene; ET, endocrine therapy; HER2, human epidermal growth factor receptor 2; HRQoL, health-related quality of life; mut, mutated; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; QD, once daily; R, randomization; TTR. time to response

Clinical trial collaboration with MEDSIR.

### Statistical and Data Analysis

- Time-to-event endpoints will be reported using Kaplan-Meier estimates.
- Two interim analyses and a final efficacy analysis are planned.
- Stratified log-rank tests will be used to assess treatment-group differences.
- In general, statistical analyses will be performed for the overall population and subgroups of the population.
- Baseline demographics and other characteristics will be descriptively summarized.

The ADELA study (NCT06382948) will evaluate the efficacy and safety of elacestrant + everolimus compared with elacestrant + placebo in patients with

#### PHASE 3 OBJECTIVES

Primary objective: Evaluate PFS based on BIRC<sup>‡</sup>

Secondary objectives: Evaluate investigatorassessed PFS, OS, ORR, CBR, DoR, TTR, best percentage of change in tumor burden,§ safety, and HRQoL

### Eligibility Criteria

#### Key Inclusion Crit

- Women (pre-\*, peri-\*, or postn
- Histologically or cytologically
- unresectable locally recurrent
- Confirmed ESR1-mutation
- PD on prior CDK4/6i + ET for Patients receiving CDK4/6i-b eligible if PD is confirmed aff than 12 months following CD
- Previously received 1-2 lines of the second seco Progression during or within is considered as a line of end
- No prior chemotherapy in the
- No prior elacestrant or other CERANs, or novel SERMs, including everolimus<sup>†</sup>
- ECOG PS 0 or 1
- Adequate bone marrow and

Receiving a LHRH analogue for >28 days prior to study BC, advanced breast cancer: CDK4/6i, cvclin-depende Group performance status: ER, endocrine receptor: ET, en normone-releasing hormone; mTOR, mammalian target of r selective estrogen receptor modulators; SOC, standard of care

### SUMMARY

- antibody-drug conjugate-based regimens.
- Recruitment for ADELA is ongoing.

Austria Brazil **Czech Republic** Spain France Greece Italy Germany UK

#### **REFERENCES**:

1. Zhao M, et al. Target Oncol. 2023;18(3):327-358. 2. Burstein HJ, et al. J Clin Oncol. 2021;39(35):3959-3977. 3. Burstein HJ. N Engl J Med. 2020;383(26):2557-2570. 4. Osborne CK, et al. Annu Rev Med. 2011;62:233-247. 5. Brett JO, et al. Breast Cancer Res. 2021;23(1):85. 6. Bidard FC, et al. Lancet Oncol. 2022;23(11):1367-1377. 7. Santiago Novello RG, et al. ESMO Open. 2023; 8(suppl 4):104409. 8. Glaviano A, et al. Mol Cancer. 2023;22(1):138. 9. Cancer Genome Atlas Network. Nature. 2012;490(7418):61-70. 10. Hartkopf AD, et al. Breast Care (Basel). 2020;15:347-54. 11. Lei JT, et al. Breast. 2019;48:S26–S30. 12. Jeselsohn R, et al. Clin Cancer Res. 2014;20(7):1757-1767. **13.** Toy W, et al. *Nat Genet*. 2013;45(12):1439-1445. **14.** Oesterreich S, et al. *Nat Genet*. 2013;45(12):1415-1416. 15. Lloyd MR, et al. Ther Adv Med Oncol. 2022;14:17588359221113694. 16. Robinson DR, et al. Nat Gen. 2013;45:1446-51. 17. Jhaveri K, et al. Ann Oncol. 2023;34(suppl 2):S334-S390. 18. Bhave MA, et al. SABCS 2023. PO2-16-05. 19. Orserdu. Prescribing information. Stemline Therapeutics; 2023. 20. Bidard FC, et al. J Clin Oncol. 2022;40:3246-3256. 21. Bardia A, et al. Clin Cancer Res. 2024;30:4299-4309. 22. Brufsky A, et al. The Oncologist. 2018;23:528–539 23. Vasan N, et al. Ann Oncol. 2019;30(suppl\_10):x3-x11. 24. Afinitor. Prescribing information. Novartis Pharmaceuticals Corporation; 2022. **25.** Bihani T et al. *Clin Cancer Res*. 2017;23(16):4793-4804. **26.** Rugo HS, et al. *Ann Oncol.* 2024;35(suppl\_2):S357-S405. Language Summary **27.** Rugo HS, et al. *J Clin Oncol*. 2024;42(16 suppl):1069. **ACKNOWLEDGMENTS:** 


We would like to thank the patients and their families who will participate in this study, as well as the ADELA team at MEDSIR and MENARINI (study sponsors) for their dedicated efforts, and to MENARINI for providing the funding for this study. Phillips Group Oncology Communications, Inc. provided professional assistance with poster developmen

ria	Key Exclusion Criteria
nenopausal) and men age ≥18 years confirmed ER+/HER2−	<ul> <li>Formal contraindication to ET defined as visceral crisis and/or rapidly or symptomatic progressive visceral disease</li> </ul>
or metastatic disease	<ul> <li>Received treatment with approved or investigational cancer therapy ≤14 days prior to randomization (except for fulvestrant that must be completed ≥28 days before randomization)</li> </ul>
BC after $\geq$ 6 months sed therapy in the adjuvant setting are $\geq$ 12 months of treatment but no more	<ul> <li>Known active uncontrolled or symptomatic CNS metastases and/or leptomeningeal disease</li> </ul>
4/6i treatment completion f ET for aBC	<ul> <li>Concurrent malignancy or malignancy ≤3 years before randomization</li> </ul>
months of adjuvant endocrine therapy crine therapy for advanced disease	<ul> <li>Clinically relevant cardiovascular or cerebrovascular disease and/or cardiac dysfunction or conduction abnormalities**</li> </ul>
advanced setting nvestigational SERDs, PROTACs, nd/or PI3K/AKT/mTOR inhibitors,	<ul> <li>History of non-infectious ILD or pneumonitis that required steroids current ILD or pneumonitis, or has suspected pneumonitis that cannot be ruled out by imaging at screening</li> </ul>
	<ul> <li>Current or prior coagulopathy ≤6 months, including history of DVT or pulmonary embolism</li> </ul>
gan function	

• ADELA, an international, multicenter, double-blind, placebo-controlled, randomized phase 3 trial, will evaluate the efficacy of elacestrant + everolimus relative to elacestrant + placebo in patients with ER+/HER2- advanced breast cancer and ESR1-mutated tumors progressing on ET + CDK4/6i.

• The primary objective is to evaluate the efficacy of elacestrant + everolimus relative to elacestrant + placebo in terms of PFS based on BIRC.

• The combination of elacestrant + everolimus may provide a novel and effective therapeutic option for patients with ER+/HER2- advanced breast cancer with ESR1-mutated tumors who progressed on ET+CDK4/6i that can potentially improve clinical outcomes and delay chemotherapy or





Copies of this poster obtained through Quick Response (QR) Code are for personal use only Response (QR) Code are for personal use only and may not be reproduced without permission from SABCS<sup>®</sup> and the author of this poster.